首頁 › 骨髓增生異常症候群 › 北卡羅來納州 › Durham
Durham, NC 的 骨髓增生異常症候群 臨床試驗
14 項針對 骨髓增生異常症候群 的研究正在 Durham（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
招募中2 期
- Duke University Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 距離 10 英里
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
招募中2 期
- Duke University Medical Center, Durham
Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
招募中1 期
- University of North Carolina at Chapel Hill, Chapel Hill · 距離 10 英里
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
招募中3 期
- Unc Lineberger Comprehensive Cancer Center, Chapel Hill · 距離 10 英里
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
招募中1/2 期
- Duke University Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 距離 10 英里
ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
招募中1 期
- University of North Carolina at Chapel Hill, Chapel Hill · 距離 10 英里
Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)
招募中1/2 期
- Duke Cancer Institute, Durham
Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
招募中1/2 期
- Research Site, Durham
- Research Site, Chapel Hill · 距離 10 英里
Registry of Older Patients With Cancer
招募中觀察性研究
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 距離 10 英里
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
招募中2/3 期
- Duke University, Durham
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
招募中1/2 期
- Duke University, Durham
- UNC Hospital, Chapel Hill · 距離 10 英里
CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
招募中1 期
- Duke Cancer Center, Durham
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
招募中觀察性研究
- Massive Bio SYNERGY-AI site, Chapel Hill · 距離 10 英里
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
招募中觀察性研究
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 距離 10 英里
其他城市的 骨髓增生異常症候群 試驗
- Houston, TX43 項研究
- Baldwin Park, CA26 項研究
- New York City, NY21 項研究
- Seattle, WA21 項研究
- Washington, DC20 項研究
- Tampa, FL19 項研究
- Boston, MA19 項研究
- Miami, FL17 項研究
- Columbus, OH14 項研究
- St. Louis, MO13 項研究
- Atlanta, GA13 項研究
- Chicago, IL13 項研究
Durham 的其他研究
- 乳癌64 項研究
- 癌症（所有類型）58 項研究
- 非小細胞肺癌39 項研究
- 多發性骨髓瘤37 項研究
- 急性髓系白血病33 項研究
- 轉移性癌症33 項研究
- 前列腺癌32 項研究
- 肺癌32 項研究
- 大腸直腸癌28 項研究
- 卵巢癌27 項研究
- 慢性淋巴性白血病27 項研究
- 心臟衰竭26 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。